Molecular insights into the pathogenesis of Alzheimer's disease and its relationship to normal aging.
- Authors
- Podtelezhnikov, Alexei A; Tanis, Keith Q; Nebozhyn, Michael; Ray, William J; Stone, David J; Loboda, Andrey P
- Year
- 2011
- Journal
- PloS one
- PMID
- 22216330
- DOI
- 10.1371/journal.pone.0029610
- PMCID
- PMC3247273
Alzheimer's disease (AD) is a complex neurodegenerative disorder that diverges from the process of normal brain aging by unknown mechanisms. We analyzed the global structure of age- and disease-dependent gene expression patterns in three regions from more than 600 brains. Gene expression variation could be almost completely explained by four transcriptional biomarkers that we named BioAge (biological age), Alz (Alzheimer), Inflame (inflammation), and NdStress (neurodegenerative stress). BioAge captures the first principal component of variation and includes genes statistically associated with neuronal loss, glial activation, and lipid metabolism. Normally BioAge increases with chronological age, but in AD it is prematurely expressed as if some of the subjects were 140 years old. A component of BioAge, Lipa, contains the AD risk factor APOE and reflects an apparent early disturbance in lipid metabolism. The rate of biological aging in AD patients, which cannot be explained by BioAge, is associated instead with NdStress, which includes genes related to protein folding and metabolism. Inflame, comprised of inflammatory cytokines and microglial genes, is broadly activated and appears early in the disease process. In contrast, the disease-specific biomarker Alz was selectively present only in the affected areas of the AD brain, appears later in pathogenesis, and is enriched in genes associated with the signaling and cell adhesion changes during the epithelial to mesenchymal (EMT) transition. Together these biomarkers provide detailed description of the aging process and its contribution to Alzheimer's disease progression.
Gene expression in PFC1.The heat map shows hierarchical clustering of the 4000 most variable genes. The samples (rows) are sorted according to the values of the first principal component of the complete dataset and labeled according to diagnosis (normal samples in black, AD samples in red on the right).
Aging score versus chronological age in PFC1.The box plots (A) demonstrate the distribution of BioAge in different 5-year long age segments and list the ANOVA p-values for the BioAge separation between normal and AD subjects in each chronological age segment. (B) Prediction of chronological age in the independent normal cohort using BioAge. The postmortem prefrontal cortex samples from individual of different age were profiled in an earlier study (GSE1572) [3]. BioAge was calculated based on average expression of several hundred genes from Table S2 (see Methods).
Disease-specific metagenes.(A) Clustered gene-gene correlation matrix demonstrating strong mutual correlations between genes that were differentially expressed between AD and non-demented samples from PFC1. Three outlined clusters correspond to NdStress, Alz, and Inflame. The coregulation of these genes is also shown in the panel (B). Each colored line represents expression levels of individual genes in 55 PFC1 samples from non-demented and AD subjects sorted in the order of increasing BioAge. Only representative samples that scored in the top or bottom 3% for any of the biomarkers were selected for this figure to improve visualization.
Plot matrix of mutual relationships between key aging and disease-specific biomarkers as well as chronological age.Each biomarker is represented by its score in each sample based on the average gene expression of contributing genes (see Methods). Non-demented PFC1 samples are shown by black dots. AD samples are shown by red dots. All pairwise relationships between the biomarkers and with chronological age are shown.
Correlation between biomarker scores in PFC1 and VC1 of the same individuals.Each plot shows relationships between the biomarker values in PFC1 and VC1. Samples from non-demented and AD subjects are shown in black and red respectively.
Comparison of NdStress and Alz in AD and HD. AD samples of PFC2 are colored in red.HD samples are colored in green. The reference biomarker scores corresponding to non demented individuals are represented by dashed lines.
Disease progression model.The trajectories of BioAge changes as a function of time reflect the relatively constant rate of aging in non-demented subjects (black), and acceleration of the rate of aging in AD (red). The dots represent the postmortem state of the brain captured by gene expression profiling. The state transition model defines several broad categories for normal brains N0–N3 and for diseased states A1 and A2. The sequence of transitions and associated gene expression biomarkers are shown by arrows.
| Name | Type |
|---|---|
| A1 local | phenotype |
| AD patients | cohort |
| AD samples local | cohort |
| Affymetrix Human Genome U133A Array local | drug |
| Affymetrix Human Genome U95 Version 2 Array local | drug |
| age | phenotype |
| aging | phenotype |
| Alz local | drug |
| Alz local | other |
| Alz | phenotype |
| Alz biomarkers local | phenotype |
| Alzheimer's disease | phenotype |
| Alz scores local | phenotype |
| Amyloid beta | drug |
| apoE | gene |
| APOE ε4-allele local | variant |
| APP | gene |
| astrocytes | phenotype |
| atrophy | phenotype |
| BioAge local | drug |
| BioAge local | other |
| BioAge local | phenotype |
| BioAge-low brains local | cohort |
| BioAge score local | cohort |
| BioAge-young patients local | cohort |
| biological aging local | phenotype |
| BMP local | gene |
| Braak stage local | phenotype |
| brain | anatomy |
| brain aging local | phenotype |
| Brain Biological Age local | phenotype |
| brain tissue sample local | anatomy |
| CASP1 | gene |
| CASP4 | gene |
| cell cycle genes | gene |
| cerebellum | anatomy |
| chronological age | phenotype |
| cognition | phenotype |
| cognitive decline | phenotype |
| cortex | anatomy |
| CR1 local | anatomy |
| cRNA | drug |
| CTSK local | gene |
| dementia | phenotype |
| DHFRL1 | gene |
| diseased samples local | phenotype |
| dorsolateral prefrontal cortex | anatomy |
| ECM | drug |
| elderly control local | cohort |
| extracellular matrix | drug |
| FN1 | gene |
| folate | drug |
| FPGS local | gene |
| GFAP | gene |
| glial proliferation | phenotype |
| gliosis | phenotype |
| GSE1297 local | cohort |
| GSE1572 local | cohort |
| Harvard Brain Tissue Resource Center | cohort |
| Harvard Brain Tissue Resource Center (HBTRC) local | cohort |
| HBTRC dataset local | cohort |
| heat shock proteins local | drug |
| HES1 | gene |
| hippocampus | anatomy |
| HLA | gene |
| Homocysteine | drug |
| hostility | phenotype |
| HSPA1A local | gene |
| HSPA1B local | gene |
| Huntington's disease | phenotype |
| IL10 | gene |
| IL16 | gene |
| IL18 | gene |
| IL1B | gene |
| Inflame local | drug |
| Inflame local | phenotype |
| Inflame biomarker local | other |
| Inflame biomarker local | phenotype |
| Lipa local | drug |
| Lipa local | phenotype |
| LIPA local | gene |
| Lipa metagene local | cohort |
| Liquid nitrogen vapor local | drug |
| M15 local | cohort |
| M16 local | cohort |
| M4/5 local | cohort |
| M9 local | cohort |
| Mapt | gene |
| McLean Hospital | cohort |
| MFAP2 local | gene |
| MFAP4 local | gene |
| Microarray dataset local | cohort |
| microglia | phenotype |
| MiniMental State Examination local | phenotype |
| MiniMental Status Examination local | phenotype |
| mitochondrial DNA damage local | drug |
| MMSE | phenotype |
| mRNA | drug |
| MTR local | gene |
| N0 local | phenotype |
| N1 local | phenotype |
| N3 local | phenotype |
| NdStress local | cohort |
| NdStress local | drug |
| NdStress local | other |
| NdStress local | phenotype |
| NdStress biomarker local | other |
| neurodegeneration | phenotype |
| neurodegenerative disorders | phenotype |
| Neurodegenerative Stress local | phenotype |
| neuronal loss | phenotype |
| neurons | phenotype |
| non-demented brain local | phenotype |
| Non-demented cohort local | cohort |
| non-demented individuals local | phenotype |
| normal | phenotype |
| normal aging | phenotype |
| Normal brain local | cohort |
| Normal brain local | phenotype |
| Normal cohort local | cohort |
| Normal non-demented brain local | phenotype |
| normal patients local | cohort |
| normal samples | cohort |
| Notch | gene |
| NTRK2 | gene |
| oncogenes local | gene |
| one-carbon/folate metabolism genes local | gene |
| oxidative stress local | drug |
| Parkinson's disease | phenotype |
| PFC | anatomy |
| PFC1 local | anatomy |
| pH | drug |
| Phase 2 | cohort |
| PI3K | gene |
| PMI | phenotype |
| population over age 85 local | cohort |
| post-mitotic neurons local | anatomy |
| PPARA | gene |
| prefrontal cortex | anatomy |
| primary visual cortex | anatomy |
| proteasome proteins local | drug |
| PSEN1 | gene |
| PSEN2 | gene |
| PSMB1 local | gene |
| PTEN | gene |
| sex | phenotype |
| SLC11A1 local | gene |
| SMAD2 local | gene |
| SMAD4 local | gene |
| STIP1 local | gene |
| straightforwardness | phenotype |
| study cohort | cohort |
| synapse loss | phenotype |
| tau protein | drug |
| TGFB local | drug |
| TGFB2 | gene |
| TNFRSF1B local | gene |
| TP53 | gene |
| TWIST1 | gene |
| VC1 local | anatomy |
| VIM | gene |
| VSIG4 | gene |
| WIF1 local | gene |
| WNT6 local | gene |
| β-amyloid | drug |
| γ-protocadherins local | gene |
No uploaded files.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| RNA alternative splicing impacts the risk for alcohol use disorder. | 2023 | 37217680 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A Machine-Learning Approach Identifies Rejuvenating Interventions in the Human Brain. | Santamaria G et al. | — | 2025 | → |
| Multi-Targeting Neuroprotective Effects of <i>Syzygium aromaticum</i> Bud Extracts and Their Key Phytocompounds against Neurodegenerative Diseases. | Sharma H et al. | — | 2023 | → |
| RNA alternative splicing impacts the risk for alcohol use disorder | Liu Y et al. | — | 2023 | — |
| RNA alternative splicing impacts the risk for alcohol use disorder. | Li R et al. | — | 2023 | → |
| Neuronal cell death mechanisms in Alzheimer's disease: An insight. | Goel P et al. | — | 2022 | → |
| Neuronal Phenotype of <i>col4a1</i> and <i>col25a1</i>: An Intriguing Hypothesis in Vertebrates Brain Aging. | Leggieri A et al. | — | 2022 | → |
| Aging-related Alzheimer's disease-like neuropathology and functional decline in captive vervet monkeys (Chlorocebus aethiops sabaeus). | Frye BM et al. | — | 2021 | → |
| Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action. | Ożarowski M et al. | — | 2021 | → |
| Is There an Interconnection between Epithelial-Mesenchymal Transition (EMT) and Telomere Shortening in Aging? | Imran SAM et al. | — | 2021 | → |
| Mechanistic Aspects of Apiaceae Family Spices in Ameliorating Alzheimer's Disease. | Sharma N et al. | — | 2021 | → |
| Principles of brain aging: Status and challenges of modeling human molecular changes in mice. | Kluever V et al. | — | 2021 | → |
| Aging: therapeutics for a healthy future. | Hodgson R et al. | — | 2020 | → |
| A logical relationship for schizophrenia, bipolar, and major depressive disorder. Part 1: Evidence from chromosome 1 high density association screen. | Zhang Z et al. | — | 2020 | → |
| Brain aging: A Ianus-faced player between health and neurodegeneration. | Vanni S et al. | — | 2020 | → |
| Current advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases. | Cano A et al. | — | 2020 | → |
| Dedifferentiation and neuronal repression define familial Alzheimer's disease. | Caldwell AB et al. | — | 2020 | → |
| The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas. | Gargini R et al. | — | 2020 | → |
| The impact of ageing on lipid-mediated regulation of adult stem cell behavior and tissue homeostasis. | Sênos Demarco R et al. | — | 2020 | → |
| Exercise Modalities Improve Aversive Memory and Survival Rate in Aged Rats: Role of Hippocampal Epigenetic Modifications. | de Meireles LCF et al. | — | 2019 | → |
| HEWL interacts with dissipated oleic acid micelles, and decreases oleic acid cytotoxicity. | Huang Q et al. | — | 2019 | → |
| Identification and Analysis of Alzheimer's Candidate Genes by an Amplitude Deviation Algorithm. | Pang C et al. | — | 2019 | → |
| Impaired Wnt Signaling in the Prefrontal Cortex of Alzheimer's Disease. | Folke J et al. | — | 2019 | → |
| Increased expression of heme-binding protein 1 early in Alzheimer's disease is linked to neurotoxicity. | Yagensky O et al. | — | 2019 | → |
| Ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer's disease. | Fessel J | — | 2019 | → |
| New Insights into the Role of Epithelial⁻Mesenchymal Transition during Aging. | Santos F et al. | — | 2019 | → |
| Aging African green monkeys manifest transcriptional, pathological, and cognitive hallmarks of human Alzheimer's disease. | Cramer PE et al. | — | 2018 | → |
| Altered expression of the Cdk5 activator-like protein, Cdk5α, causes neurodegeneration, in part by accelerating the rate of aging. | Spurrier J et al. | — | 2018 | → |
| Comparative transcriptomics of choroid plexus in Alzheimer's disease, frontotemporal dementia and Huntington's disease: implications for CSF homeostasis. | Stopa EG et al. | — | 2018 | → |
| Human Age Prediction Based on DNA Methylation Using a Gradient Boosting Regressor. | Li X et al. | — | 2018 | → |
| Human Alzheimer's disease gene expression signatures and immune profile in APP mouse models: a discrete transcriptomic view of Aβ plaque pathology. | Rothman SM et al. | — | 2018 | → |
| Immunohistochemical Analysis of Activin Receptor-Like Kinase 1 (ACVRL1/ALK1) Expression in the Rat and Human Hippocampus: Decline in CA3 During Progression of Alzheimer's Disease. | Adams SL et al. | — | 2018 | → |
| Integrative Analysis of Hippocampus Gene Expression Profiles Identifies Network Alterations in Aging and Alzheimer's Disease. | Lanke V et al. | — | 2018 | → |
| Markers of microglia in post-mortem brain samples from patients with Alzheimer's disease: a systematic review. | Hopperton KE et al. | — | 2018 | → |
| Neural stem cells and adult brain fatty acid metabolism: Lessons from the 3xTg model of Alzheimer's disease. | Hamilton LK et al. | — | 2018 | → |
| The role of Twist1 in mutant huntingtin-induced transcriptional alterations and neurotoxicity. | Pan Y et al. | — | 2018 | → |
| Identification of Novel Key Molecules Involved in Spatial Memory Impairment in Triple Transgenic Mice of Alzheimer's Disease. | Ying M et al. | — | 2017 | → |
| Neuron-specific methylome analysis reveals epigenetic regulation and tau-related dysfunction of BRCA1 in Alzheimer's disease. | Mano T et al. | — | 2017 | → |
| The Past, Present, and Future of Phosphodiesterase-4 Modulation for Age-Induced Memory Loss. | Hansen RT et al. | — | 2017 | → |
| Ageing, neurodegeneration and brain rejuvenation. | Wyss-Coray T | — | 2016 | → |
| Changes in the Chemical Barrier Composition of Tears in Alzheimer's Disease Reveal Potential Tear Diagnostic Biomarkers. | Kalló G et al. | — | 2016 | → |
| Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. | Jaeger PA et al. | — | 2016 | → |
| Transcriptional Analysis of Blood Lymphocytes and Skin Fibroblasts, Keratinocytes, and Endothelial Cells as a Potential Biomarker for Alzheimer's Disease. | Mukhamedyarov MA et al. | — | 2016 | → |
| Aberrant Lipid Metabolism in the Forebrain Niche Suppresses Adult Neural Stem Cell Proliferation in an Animal Model of Alzheimer's Disease. | Hamilton LK et al. | — | 2015 | → |
| dbEMT: an epithelial-mesenchymal transition associated gene resource. | Zhao M et al. | — | 2015 | → |
| Gene expression parallels synaptic excitability and plasticity changes in Alzheimer's disease. | Saura CA et al. | — | 2015 | → |
| Genome-wide epistatic expression quantitative trait loci discovery in four human tissues reveals the importance of local chromosomal interactions governing gene expression. | Fitzpatrick DJ et al. | — | 2015 | → |
| Shared genetic etiology underlying Alzheimer's disease and type 2 diabetes. | Hao K et al. | — | 2015 | → |
| Common dysregulation network in the human prefrontal cortex underlies two neurodegenerative diseases. | Narayanan M et al. | — | 2014 | → |
| Early and sustained altered expression of aging-related genes in young 3xTg-AD mice. | Gatta V et al. | — | 2014 | → |
| Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. | Morris GP et al. | — | 2014 | → |
| In vivo optical signatures of neuronal death in a mouse model of Alzheimer's disease. | Lin AJ et al. | — | 2014 | → |
| Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease. | Hanzel CE et al. | — | 2014 | → |
| A preliminary study of the whole-genome expression profile of sporadic and monogenic early-onset Alzheimer's disease. | Antonell A et al. | — | 2013 | → |
| Biobanking across the phenome - at the center of chronic disease research. | Imboden M et al. | — | 2013 | → |
| Systems biology approach for new target and biomarker identification. | Wang IM et al. | — | 2013 | → |
| The airbag problem-a potential culprit for bench-to-bedside translational efforts: relevance for Alzheimer's disease. | Krstic D et al. | — | 2013 | → |
| Brain-derived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder. | Tripp A et al. | — | 2012 | → |
| Editors' Pick: Normal aging versus Alzheimer's disease - expression patterns may discern the differences. | Budowle B | — | 2012 | → |
| Transcriptional alterations related to neuropathology and clinical manifestation of Alzheimer's disease. | Silva AR et al. | — | 2012 | → |